Olema Oncology Announces $54 Million Series B Financing
Proceeds will be used to advance lead program in breast cancer into Phase 1/2 clinical development
Financing co-led by BVF Partners L.P., Logos Capital and Janus Henderson Investors
SAN FRANCISCO, July 22, 2020 -- (Healthcare Sales & Marketing Networ... Biopharmaceuticals, Oncology, Venture Capital, Personnel Olema Oncology, complete estrogen receptor antagonist, breast cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Marketing | Pharmaceuticals | Venture Capital